Abstract Details

Title No ‘Wearing-Off Effect’ Seen with Fremanezumab in the Real-World: Retrospective, Claims-Based Analysis of Migraine-Related Healthcare Resource and Acute Medication Use

Topic Headache

Presentation(s) P12 - Poster Session 12 (5:30 PM-6:30 PM)

Poster/Presentation
Number 2-005

Objective

To assess weekly patterns in migraine-related healthcare resource use (HCRU) and acute medication use, as proxy for wearing-off with fremanezumab, in US adult migraine patients.

Background

Wearing-off is the phenomenon whereby clinical symptoms return/worsen before the next scheduled treatment dose. Post-hoc data showed no evidence of wearing-off with monthly and quarterly dose fremanezumab; no respective real-world data are available.

Design/Methods

This retrospective, observational US claims database analysis included adult migraine patients with ≥2 fremanezumab claims in monthly treatment cycles. The proportions of patients with ≥1 migraine-related HCRU (inpatient, emergency room, outpatient visit or ≥1 migraine-related acute medication claim were descriptively assessed at Weeks 1, 2, 3, and 4 of Cycles 1, 3, 6, and 12. Confidence intervals (CI) at 95% were calculated; overlapping CIs indicated no statistically significant trends in the week-to-week outcome values within each cycle, indicating no wearing-off. Sensitivity analysis examined weekly HCRU and acute medication use during the first 24 cycles.

Results During all assessed monthly dosing cycles (N=3217), there were no significant trends indicating wearing-off in migraine-related HCRU or acute medication use. In Cycle 1, the 95% CIs for patients with ≥1 migraine-related outpatient visit at Weeks 1, 2, 3, and 4 overlapped: [5.41%, 7.28%], [4.56%, 6.29%], [5.38%, 7.24%] and [4.93%, 6.73%] respectively. Similarly, 95% CIs for patients with ≥1 migraine-related triptan use were [5.14%, 6.97%], [4.69%, 6.45%], [4.56%, 6.29%] and [5.72%, 7.64%]. Similar trends were observed across Cycles 3, 6, and 12 for all outcomes. Notably, outpatient visits decreased during Cycle 3. Sensitivity analysis confirmed there were no significant trends in outcome values across Cycles 1–24. Quarterly dosing results showed similar trends.

Conclusions

Over monthly dosing cycles of fremanezumab, no increases in migraine-related HCRU and acute medication use were seen, representing no evidence of wearing-off with fremanezumab and confirming post-hoc findings.

Authors/Disclosures
Mario Ortega, PhD (Teva Pharmaceuticals) PRESENTER	Dr. Ortega has received personal compensation for serving as an employee of Teva Pharmaceuticals.
Jessica Ailani, MD, FAAN (Medstar Georgetown Neurology)	Dr. Ailani has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Abbvie. Dr. Ailani has received personal compensation in the range of $0-$499 for serving as a Consultant for Eli Lilly. Dr. Ailani has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Ailani has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ipsen. Dr. Ailani has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Merz. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Aspya. Dr. Ailani has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axsome. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bausch. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amneal. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Satsuma. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Kallyope. Dr. Ailani has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Self Magazine. The institution of Dr. Ailani has received research support from Ipsen. The institution of Dr. Ailani has received research support from Parema. The institution of Dr. Ailani has received research support from Lundbeck. The institution of Dr. Ailani has received research support from Merz. The institution of Dr. Ailani has received research support from Pfizer. Dr. Ailani has received research support from Mi-Helper. The institution of Dr. Ailani has received research support from ShiraTronic. Dr. Ailani has a non-compensated relationship as a Executive Board Member with American Headache Society that is relevant to AAN interests or activities.
	No disclosure on file
Maurice Driessen (Teva)	No disclosure on file
	No disclosure on file
Verena Ramirez Campos, MD (Teva)	Dr. Ramirez Campos has received personal compensation for serving as an employee of teva.
	No disclosure on file

��ɫ��

��ɫ��